Home > Journals > Minerva Gastroenterology > Past Issues > Articles online first > Minerva Gastroenterology 2022 Feb 10



Publishing options
To subscribe
Submit an article
Recommend to your librarian


Publication history
Cite this article as



Minerva Gastroenterology 2022 Feb 10

DOI: 10.23736/S2724-5985.22.03139-4


language: English

Non-invasive biomarkers of non-alcoholic fatty liver disease in patients with Metabolic Syndrome: insights from the RESOLVE study

Gaël ENNEQUIN 1 , Benjamin BUCHARD 2, Bruno PEREIRA 3, Line BONJEAN 1, Daniel COURTEIX 1, Bruno LESOURD 1, Robert CHAPIER 1, Philippe OBERT 4, Agnes VINET 4, Guillaume WALTHER 4, Marek ZAK 5, Reza BAGHERI 6, Chris U. UGBOLUE 7, Armand ABERGEL 2, 8, Frédéric DUTHEIL 9, David THIVEL 1

1 Université Clermont Auvergne, CRNH, AME2P, Clermont-Ferrand, France; 2 Department of Digestive and Hepatobiliary Medecine, CHU Clermont-Ferrand, Clermont-Ferrand, France; 3 Biostatistics Unit, DRCI, University Hospital of Clermont-Ferrand, CHU Clermont-Ferrand, Clermont-Ferrand, France; 4 Laboratoire de Pharm-écologie Cardiovasculaire (LAPEC) EA4278, Avignon University, Avignon, France; 5 The Institute of Health Sciences, Collegium Medicum, The Jan Kochanowski University, Kielce, Poland; 6 Department of Exercise Physiology, University of Isfahan, Isfahan, Iran; 7 School of Health and Life Sciences, Institute for Clinical Exercise & Health Science, University of the West of Scotland, Glasgow, UK; 8 UMR CNRS 6284, Clermont Auvergne University, Clermont-Ferrand, France; 9 Université Clermont Auvergne, CNRS, LaPSCo, Physiological and Psychosocial Stress, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Preventive and Occupational Medicine, Witty Fit, Clermont-Ferrand, France

BACKGROUND: The aim of the present study was to evaluate i) the presence of liver steatosis using Fatty Liver Index (FLI), Hepatic Steatosis Index (HSI) and Liver Fat Score (LFS) in patients suffering from MS and ii) the association of FLI, HSI and LFS with the cardiometabolic risks.
METHODS: A total of 91 patients with MS (MS; 39 men, 52 women) and 44 age matched healthy subjects (Control; 23 men and 21 women) were enrolled in the study. A continuous cardiometabolic score (MetsScore) and the noninvasive tests of hepatic steatosis were calculated for comparison and association analysis.
RESULTS: Liver steatosis was detected in 86%, 84% and 80% of people diagnosed with MS using FLI, HSI and LFS respectively and MetsScore increases with FLI severity (p<0,05). Also, FLI and LFS were positively associated with MetsScore (p<0.01 and p<0.05 respectively) but not HSI. Multivariate linear regression models revealed that FLI has a stronger association with MetsScore compared with HSI and LFS (p<0,001).
CONCLUSIONS: FLI is associated with the severity of MS and represent a good indicator to assess the relation between liver steatosis and a cardiometabolic disorders in clinical routine.

KEY WORDS: Metabolic syndrome; Non-alcoholic fatty liver disease; Fatty liver index; Hepatic steatosis index; Liver fat score

top of page